Liraglutide
Evidence: A — Established Human EvidenceMetabolic / Weight Management
Evidence Snapshot
What this grade covers
A for FDA-approved product-specific uses of Saxenda and Victoza and their pivotal outcome trials; D for compounded/lyophilized equivalence claims, microdosing, anti-aging, or stacking claims.
Regulatory Context
FDA approval applies to Saxenda and Victoza as finished products. It does not establish equivalence of compounded, lyophilized, or research liraglutide. FDA's 2026 proposal concerning the 503B bulks list addresses outsourcing-facility compounding and does not revoke approved-product indications.
Research Takeaway
Liraglutide is a GLP-1 receptor agonist and is the active ingredient in FDA-approved products including Saxenda and Victoza; it is distinct from semaglutide, tirzepatide, and retatrutide.
Evidence boundary: Shared incretin pharmacology does not make GLP-1-based drugs therapeutically or dose-equivalent.
See all 6 evidence claims →Quick Summary
Liraglutide is a once-daily GLP-1 receptor agonist available in FDA-approved product-specific forms. Saxenda is approved for chronic weight management in qualifying adults and adolescents, while Victoza is approved for type 2 diabetes and cardiovascular-risk reduction in a defined adult diabetes population.
Mechanism & Research Overview
Liraglutide is a long-acting glucagon-like peptide-1 receptor agonist administered once daily. It improves glucose-dependent insulin secretion, reduces inappropriate glucagon secretion, delays gastric emptying, and reduces energy intake. Liraglutide is distinct from semaglutide, tirzepatide, retatrutide, and other incretin drugs; evidence and dosing must not be transferred across molecules.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
Liraglutide is a GLP-1 receptor agonist and is the active ingredient in FDA-approved products including Saxenda and Victoza; it is distinct from semaglutide, tirzepatide, and retatrutide.
Does not establish
Evidence boundary: Shared incretin pharmacology does not make GLP-1-based drugs therapeutically or dose-equivalent.
Sources: Victoza Prescribing Information
Supported
Liraglutide is FDA-approved in product-specific programs for chronic weight management and for type 2 diabetes, with indications and dosing that differ between Saxenda and Victoza.
Does not establish
Evidence boundary: Approval of one liraglutide product or dose does not automatically establish another indication or dose.
Sources: Saxenda Approval Letter June 2026; Victoza Prescribing Information
Supported
Randomized obesity trials demonstrate clinically meaningful weight reduction with liraglutide 3.0 mg plus lifestyle intervention compared with placebo in adults and adolescents studied in the Saxenda development program.
Does not establish
Evidence boundary: Liraglutide results must not be replaced with larger weight-loss percentages reported for semaglutide, tirzepatide, or retatrutide.
Sources: SCALE Obesity and Prediabetes Trial
Supported
Liraglutide labeling includes important gastrointestinal, gallbladder, pancreatitis, hypoglycemia, and thyroid C-cell-tumor-related warnings and contraindications that vary with clinical context.
Does not establish
Evidence boundary: This summary is not a substitute for current product labeling and does not establish individual risk.
Sources: Victoza Prescribing Information
Supported
Weight-management evidence for Saxenda 3.0 mg should not be attributed to lower-dose Victoza treatment or transferred to unapproved compounded products without evidence of equivalence.
Does not establish
Evidence boundary: Same active ingredient does not make every dose, formulation, indication, or unapproved product evidentially interchangeable.
Sources: SCALE Obesity and Prediabetes Trial; Victoza Prescribing Information
Supported
Only FDA-label or named-trial dosing may appear as Study/Trial Dosing; no consumer titration, injection, or weight-loss protocol is provided by this package.
Does not establish
Evidence boundary: Label dosing is prescription context and must not be personalized by the content pipeline.
Sources: SCALE Obesity and Prediabetes Trial
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Observed in rodents; human relevance unknown. Contraindicated with personal or family history of medullary thyroid carcinoma or MEN2.Safety Consideration
Discontinue if pancreatitis is suspected; acute gallbladder disease has also been reported.Safety Consideration
Compounded, lyophilized, or research liraglutide is not FDA approved and is not established as equivalent to Saxenda or Victoza in identity, potency, sterility, or effectiveness.Safety Consideration
Separate, non-interchangeable indications and dosing; evidence and dosing must not be transferred between them or to other incretin drugs (semaglutide, tirzepatide, retatrutide).
Research Areas Being Studied
Research areas discussed on this page reflect the Metabolic / Weight Management category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
- SCALE Obesity and Prediabetes Trial ():
Study Tables by Evidence Type
Human Studies & Clinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| SCALE Obesity and Prediabetes Trial | 3,731 adults without diabetes were randomized to liraglutide 3.0 mg or placebo with lifestyle intervention for 56 weeks. Mean weight loss was approximately 8.4 kg with liraglutide versus 2.8 kg with placebo; more liraglutide-treated participants achieved at least 5% and more than 10% weight loss. These are group averages under a controlled trial and do not guarantee individual results. |
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Saxenda Approval Letter June 2026 | 2026 | FDA's June 2026 supplement approval letter for Saxenda (NDA 206321), confirming continued FDA approval of the finished product. | |||
| Victoza Prescribing Information | 2025 | Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, and to reduce major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Saxenda's weight-management indication must not be transferred to Victoza, nor Victoza's diabetes/cardiovascular indication to Saxenda.
|
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Nothing on this page is a prescription, dosing instruction, or substitute for product-specific FDA labeling. Saxenda and Victoza have separate approved indications and dosing that must not be interchanged, and compounded liraglutide is not established as equivalent to either finished product.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-07-26.
Follow research updates for Liraglutide
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.